BRISBANE, Calif. / Feb 27, 2024 / Business Wire / CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that the company will be participating in the upcoming Raymond James & Associates’ 45th Annual Institutional Investors Conference.
CareDx’s management is scheduled to present on Wednesday, March 6, 2024, at 9:50 a.m. Eastern Standard Time. Interested parties may access a live audio webcast by visiting the “Investors” section of the company’s website at investors.CareDx.com.
About CareDx – The Transplant Company
CareDx, Inc., headquartered in Brisbane, California, is a leading precision medicine solutions company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the leading provider of genomics-based information for transplant patients. For more information, please visit www.CareDx.com.
Last Trade: | US$14.73 |
Daily Change: | -0.06 -0.41 |
Daily Volume: | 767,494 |
Market Cap: | US$784.080M |
August 06, 2025 August 06, 2025 July 18, 2025 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREAmneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MOREEnd of content
No more pages to load